James H. Garvin Jr., MD, PhD

Expertise in: 
Cancer Care
Board Certifications: 
Pediatric Hematology-Oncology, Pediatrics
Accepting New Patients
Treats Children
Profile Headshot

Overview

Areas of Expertise / Conditions Treated

Cancer Care, Chemotherapy, Anemia, Iron Deficiency, Leukemia, Bone Marrow Transplant, Pediatric Brain Tumors

Academic Appointments

  • Professor of Pediatrics at CUMC

James H. Garvin, MD, PhD, is a board-certified pediatric hematologist-oncologist who specializes in the care of children and adolescents with brain tumors. He is Principal Investigator at CUMC for the Head Start Program of radiation-sparing intensive chemotherapy for infants and young children with brain tumors. He was principal investigator for a Children's Oncolgy Group protocol for childhood ependymoma. He also offers novel therapies for recurrent brain tumors through our program's membership in Developmental Therapeutics Program of the COG. 

In addition, Dr. Garvin started the pediatric bone marrow transplant program, and continues as a member of the BMT group. He has particular interest in autologous transplant for brain tumors and allogeneic transplant for metabolic disorders and bone marrow failure syndromes, as well as supportive care for BMT patients. 

Dr. Garvin became interested in pediatric hematology/oncology through research during medical school in the laboratory of a pediatric hematologist. He is a member of numerous professional societies in the field. 

Hospital Affiliations

  • NewYork-Presbyterian/Morgan Stanley Children's Hospital
  • NewYork-Presbyterian/Columbia

Gender

  • Male

Schedule an Appointment

Phone Appointments

New and Existing Patients:
212-305-5808

Location(s)

CUMC/Herbert Irving Pavilion
161 Fort Washington Avenue
New York, NY 10032
Primary

Insurance Accepted

Aetna

  • EPO
  • HMO
  • Medicare Managed Care
  • NY Signature
  • NYP Employee Plan
  • POS
  • PPO
  • Signature Administrators
  • Student Health

Affinity

  • Essential Plan
  • Medicaid Managed Care

Amida Care

  • Special Needs Plan

Cigna

  • EPO
  • Great West
  • HMO
  • POS
  • PPO

Emblem/GHI

  • Medicare Managed Care
  • PPO

Emblem/HIP

  • ConnectiCare
  • EPO
  • Essential Plan
  • HMO
  • Medicaid Managed Care
  • Medicare Managed Care
  • POS
  • PPO
  • Select Care (Exchange)
  • Vytra

Empire Blue Cross Blue Shield

  • Blue Access (Exchange)
  • EPO
  • Gatekeeper (Exchange)
  • HMO
  • Medicare Managed Care
  • Pathway (Exchange)
  • POS
  • PPO

Empire Blue Cross Blue Shield HealthPlus

  • Child/Family Health Plus
  • Essential Plan
  • Medicaid Managed Care

Fidelis Care

  • Child/Family Health Plus
  • Medicaid Managed Care
  • Medicare Managed Care

Healthfirst

  • Child/Family Health Plus
  • Leaf (Exchange)
  • Medicaid Managed Care
  • Medicare Managed Care

Local 1199

  • Local 1199

MagnaCare

  • MagnaCare

Medicare

  • Traditional Medicare (NY)

Multiplan

  • Multiplan

MVP Health Care

  • MVP Health Care-Hudson Health Plan

Oxford Health Plans

  • Freedom
  • Liberty
  • Medicare Managed Care

TRICARE

  • TRICARE

UnitedHealthcare

  • Columbia University Employee Plan
  • Compass (Exchange)
  • Essential Plan
  • HMO
  • Medicaid (Community Plan)
  • Medicare Managed Care
  • POS
  • PPO
  • The Empire Plan (NYSHIP)

VNSNY CHOICE

  • Medicare Managed Care
  • SelectHealth

WellCare

  • Medicaid Managed Care
  • Medicare Managed Care

*Please contact the provider’s office directly to verify that your particular insurance is accepted.

Credentials & Experience

Education & Training

  • Thomas Jefferson University Medical College
  • Internship: Children's Hospital of Philadelphia
  • Residency: Children's Hospital of Philadelphia
  • Fellowship: Dana-Farber Cancer Institute, MA

Board Certifications

  • Pediatric Hematology-Oncology
  • Pediatrics
America's Top Doctor
NY Top Doctor

Research

Grants

NEWLY DIAGNOSED CHILDREN (LESS THAN 10 YEARS OLD) WITH MEDULLOBLASTOMA AND OTHER CENTRAL NERVOUS SYSTEMPRIMITIVE NEURO-ECTODERMAL TUMORS: CLINICAL AND MOLECULAR RISK-TAILORED INTENSIVE AND COMPRESSED INDUCTION CHEMOTHERAPY FOLLOWED BY CONSILIDATION WITH (Private)

Jul 1 2016 - Jun 30 2017